Halozyme Therapeutics Inc (NASDAQ:HALO)

19.28
Delayed Data
As of 4:15pm ET
 +0.04 / +0.21%
Today’s Change
11.41
Today|||52-Week Range
21.13
-4.84%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 4
2016
Quarter 1
2017
Quarter 2
2017
Quarter 3
2017
Revenue and IncomeNet Revenues39.0M29.6M33.8M63.7M
 
 
 
 
 
Cost of Goods Sold7.4M6.9M7.2M7.8M
 
 
 
 
 
Depreciation And Amortization644.0K602.0K600.0K500.0K
 
 
 
 
 
 
Operating ExpensesGross Income31.0M22.0M26.0M55.4M
 
 
 
 
 
General Expenses53.6M49.6M51.4M47.3M
 
 
 
 
 
Research And Development41.3M36.9M38.3M34.0M
 
 
 
 
 
Total Operating Expenses61.6M57.1M59.2M55.7M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-22.6M-27.5M-25.5M8.1M
 
 
 
 
 
Interest Expense On Debt5.6M5.4M5.5M5.5M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-27.8M-32.7M-30.6M3.3M
 
 
 
 
 
Income Taxes-422.0K-210.0K-180.0K-580.0K
 
 
 
 
 
Net Income-27.4M-32.9M-30.8M2.7M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS128.2M128.6M134.0M141.2M
 
 
 
 
 
Shares To Calculate EPS Diluted128.2M128.6M134.0M143.2M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.21-$0.26-$0.23$0.02
 
 
 
 
 
EPS Diluted-$0.21-$0.26-$0.23$0.02